Please assess the completion status of the following clinical trial:

Trial Title: A Study of Remote Electrical Neuromodulation for Acute Procedural Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the criteria for 1.3 chronic migraine based on ICHD3 criteria.~* Currently receiving onabotulinumtoxinA per PREEMPT protocol for the treatment of chronic migraine.~* Have remained stable on their current headache medication for a minimum of 8 weeks.~* Patient is willing and able to comply with the protocol to the satisfaction of the investigator.~* Patient has the capacity to provide written, informed consent for themselves.~Exclusion Criteria:~* Participants with an active implanted electrical and/or neurostimulator device (e.g., cardiac pacemaker, cochlear implant).~* Participants with congestive heart failure (CHF), severe cardiac or cerebrovascular disease.~* Participants with uncontrolled epilepsy.~* Change in migraine preventive medications (type or dose) in the last two months prior to recruitment and/or during the study.~* Pregnant, trying to get pregnant or breastfeeding female participants.~* Subjects participating in any other interventional clinical study.~* Participants with other significant pain, medical or psychological problems that in the opinion of the investigator may confound the study assessments.~* Participants who have previous experience with the device.~* Patients with cranial deformities, prior cranial surgeries with violation of the calvarium, or shunt placement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Electrical Neuromodulation, Then Sham (Type: EXPERIMENTAL): Subjects will first have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
- Sham, Then Electrical Neuromodulation (Type: EXPERIMENTAL): Subjects will first have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).